#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Marginal zone lymphoma recurrent Basal cell naevus syndrome Thrombocytopenia Kawasaki's disease Pancreatic carcinoma metastatic Congenital pseudarthrosis Peripheral primitive neuroectodermal tumour of soft tissue Chronic graft versus host disease in intestine Burkitt's lymphoma Systemic sclerosis pulmonary Hormone-dependent prostate cancer Squamous cell carcinoma of the vulva Myelofibrosis Cerebral amyloid angiopathy Ischaemic stroke More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis II – Trials in Disease Lymphangioma Myelodysplastic syndrome with excess blasts – Trials in Disease Focal segmental glomerulosclerosis – Diagnostics Leukoencephalopathy – Diagnostics Marfan’s syndrome – Life with Disease Glomerulonephritis rapidly progressive – Diagnostics Acute respiratory distress syndrome – Diagnostics Crigler-Najjar syndrome Glycogen storage disease type I – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    VALACICLOVIR HYDROCHLORIDE Treg02 Deupirfenidone Dydrogesterone Sodium Phenylbutyrate Biotin ANXV Sodium Picosulfate Valproic Acid Mva-209-Fsp-B3 Ondansetron Palbociclib Ads-010 Neridronate Sodium Blinatumomab Imifoplatin AMODIAQUINE LTG-001 Eltrombopag Lomustine More therapies…

    Learn about Your Condition

    Poor quality sleep Eosinophilic oesophagitis Angiosarcoma recurrent Nasopharyngeal cancer Breast cancer stage II Urinary tract infection Adenosquamous cell lung cancer Sarcoma metastatic Postoperative wound infection Anaplastic thyroid cancer Acute myeloid leukaemia Gestational diabetes Bone marrow failure Major depression Retroperitoneal fibrosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Niepubliczny Zakład Opieki Zdrowotnej Vivamed Jadwiga…

Niepubliczny Zakład Opieki Zdrowotnej Vivamed Jadwiga Miecz

Ul. Zamiejska 17, Warsaw, 03-580, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study of mirikizumab and tirzepatide for adults with moderate to severe Crohn’s disease who are overweight or obese

    Recruiting

    3 1
    Investigated Drugs:
    • Mirikizumab
    • Tirzepatide
    Austria Belgium Bulgaria Czechia Denmark France +9

  • A study testing XmAb942 compared to placebo in adults with moderate-to-severe active ulcerative colitis

    Recruiting

    2 1
    Investigated Drugs:
    • XMAB942
    Bulgaria Croatia France Germany Greece Hungary +5

  • Study of MT-501 in patients with active Crohn’s Disease or Ulcerative Colitis: A Phase 2 safety and effectiveness trial

    Recruiting

    2 1
    Investigated Diseases:
    • Crohn’s disease
    • Colitis ulcerative
    Belgium Bulgaria Croatia Czechia Germany Italy +2

  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease

    Recruiting

    3 1
    Investigated Drugs:
    • Tulisokibart
    Austria Belgium Croatia Czechia Denmark Finland +15

  • Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn’s Disease

    Recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Ro7790121
    Austria Belgium Bulgaria Croatia Czechia France +8

  • Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn’s Disease After Inadequate Response to Other Treatments

    Recruiting

    2 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Obefazimod
    Belgium Czechia France Germany Hungary Italy +5

  • Long-term safety study of tulisokibart in adults with Crohn’s disease or ulcerative colitis

    Recruiting

    3 1
    Investigated Drugs:
    • Tulisokibart
    Czechia France Hungary Poland

  • A study to evaluate the effectiveness and safety of tulisokibart and placebo in patients with moderate to severe ulcerative colitis

    Not recruiting

    3 1
    Investigated Drugs:
    • Tulisokibart
    Austria Belgium Bulgaria Croatia Czechia Finland +15

  • A study to evaluate the efficacy and safety of vixarelimab in patients with moderate to severe ulcerative colitis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Vixarelimab
    • Azathioprine
    • Adalimumab
    Belgium Czechia France Germany Greece Italy +1

  • A study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn’s disease or ulcerative colitis

    Not recruiting

    2 1
    Austria Belgium Bulgaria Croatia Czechia France +8
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!